Germany's Bayer has proposed that Jeffrey Ubben, one of Wall Street's most prominent activist investors, be appointed as a non-executive director, it said on Thursday, as it announced a leadership change at its consumer products unit. The changeover comes as the diversified group faces a deluge of problems including stifling debt, U.S. litigation alleging harm from a weed-killer, a major drug development setback, weak agriculture markets and investor pressure to separate or sell businesses. Ubben, who is a member of Bayer's sustainability council, has been among a number of investors who have long urged the company to consider a break-up, but he has kept a low profile.
Bayer proposes Ubben for board seat, swaps consumer unit boss streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning and welcome to Syros Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section of Syros’ website at www.syros.com. Please be advised that today’s call is being recorded. […]
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.